XML 39 R25.htm IDEA: XBRL DOCUMENT v3.21.1

REVENUES (Tables)

3 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenues

Revenues were as follows:

						Three Months Ended March 31, 2021																								Three Months Ended March 31, 2020
(in millions)						U.S.						Europe						Other International						Total						U.S.						Europe						Other International						Total
Product Sales:
HIV
Atripla						$	23					$	4					$	4					$	31					$	81					$	7					$	7					$	95
Biktarvy						1,465						216						143						1,824						1,412						181						100						1,693
Complera/Eviplera						25						34						4						63						24						47						5						76
Descovy						282						42						35						359						363						61						34						458
Genvoya						506						106						61						673						612						151						61						824
Odefsey						240						113						14						367						269						127						13						409
Stribild						31						11						4						46						34						17						2						53
Truvada						119						7						9						135						383						8						15						406
Other HIV(1)						6						1						10						17						3						2						3						8
Revenue share - Symtuza (2)						89						44						2						135						72						38						2						112
Total HIV						2,786						578						286						3,650						3,253						639						242						4,134
Hepatitis C virus (“HCV”)
Ledipasvir/Sofosbuvir(3)						19						16						21						56						53						11						48						112
Sofosbuvir/Velpatasvir (4)						214						75						92						381						311						122						131						564
Other HCV(5)						25						44						4						73						34						15						4						53
Total HCV						258						135						117						510						398						148						183						729
Hepatitis B virus (“HBV”) / Hepatitis Delta virus (“HDV”)
Vemlidy						77						8						96						181						73						7						56						136
Viread						4						7						20						31						4						11						25						40
Other HBV/HDV(6)						—						8						—						8						8						2						—						10
Total HBV/HDV						81						23						116						220						85						20						81						186
Veklury						820						388						248						1,456						—						—						—						—
Cell Therapy
Tecartus						27						4						—						31						—						—						—						—
Yescarta						92						61						7						160						103						37						—						140
Total Cell Therapy						119						65						7						191						103						37						—						140
Trodelvy						72						—						—						72						—						—						—						—
Other
AmBisome						12						66						43						121						18						59						42						119
Letairis						54						—						—						54						83						—						—						83
Ranexa						3						—						—						3						8						—						—						8
Zydelig						8						7						—						15						8						12						—						20
Other(7)						27						13						8						48						33						12						3						48
Total Other						104						86						51						241						150						83						45						278
Total product sales						4,240						1,275						825						6,340						3,989						927						551						5,467
Royalty, contract and other revenues						20						61						2						83						17						48						16						81
Total revenues						$	4,260					$	1,336					$	827					$	6,423					$	4,006					$	975					$	567					$	5,548

_______________________________

(1)     Includes Emtriva and Tybost.

(2)     Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

(3)     Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.

(4)     Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.

(5)     Includes Vosevi and Sovaldi.

(6)     Includes Hepcludex and Hepsera.

(7)     Includes Cayston and Jyseleca.

Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:

						Three Months Ended
						March 31,
(as a percentage of total revenues)						2021						2020
AmerisourceBergen Corporation						27		%				22		%
Cardinal Health, Inc.						18		%				22		%
McKesson Corporation						17		%				21		%

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration